CLINICAL UPDATES · SEASON 1 · EPISODE 7

IgA Nephropathy: The Modern Treatment Landscape

IgA nephropathy is the commonest glomerular disease in the world, yet until recently its treatment barely changed for decades. This Clinical Update reviews how the disease presents and is confirmed, why proteinuria drives decisions, and the new generation of targeted therapies that has finally expanded the options.

By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026

MedicalVideos Clinical Updates is an educational series produced with full editorial independence. If an episode is sponsor-funded, that funding is labelled on the episode page and on the series hub.

In short: IgA nephropathy is an immune-deposit disease of the kidney filters, diagnosed by biopsy and tracked mainly by proteinuria. Optimised supportive care is the foundation; newer targeted therapies — gut-directed steroid, dual receptor blockade, complement inhibitors — serve patients at high risk of progression.

The update

The clinical picture

IgA nephropathy is the most common primary glomerular disease worldwide. Its hallmark is IgA-dominant immune deposits in the glomerular mesangium, seen on kidney biopsy. The abnormal IgA is thought to arise largely from mucosal immunity — which is why episodes of visible blood in the urine classically appear within a day or two of a throat infection, a pattern called synpharyngitic hematuria. Course varies enormously: some patients have isolated urinary abnormalities for life, while others lose kidney function steadily, driven mainly by the level of proteinuria over time. Hypertension and scarring on biopsy add prognostic weight.

The current landscape

Treatment has been transformed in the last few years. Targeted-release budesonide, designed to act on gut mucosal immunity where much abnormal IgA originates, became the first therapy approved specifically for IgA nephropathy in several regions. Dual endothelin–angiotensin receptor blockade (sparsentan) has shown proteinuria reduction beyond standard blockade. Complement-pathway inhibitors have entered late-stage development and early approvals in some regions, reflecting the disease's immune mechanism. SGLT2 inhibitors, proven in CKD broadly, are part of the supportive backbone. KDIGO's glomerular disease guideline organises this into optimised supportive care first, then risk-based addition of disease-targeted therapy — with clinical trials actively recruiting at every step.

In practice

Diagnosis requires biopsy — blood and urine tests cannot confirm it — and biopsy also excludes mimics and grades chronic damage. Management begins with optimised supportive care for every patient: blood-pressure control, maximally tolerated renin–angiotensin blockade, SGLT2 inhibition where appropriate, salt restriction, weight and smoking management, and cardiovascular risk reduction. Proteinuria is the treatment compass, rechecked at regular intervals; patients whose proteinuria settles to low levels on supportive care alone may need nothing more. Those who remain at high risk are counselled about targeted therapies and trials, balancing expected benefit against immunosuppression burdens.

When to escalate

Escalate when proteinuria remains high despite months of optimised supportive care — that is the trigger to discuss targeted therapy or trial entry. Rapidly falling eGFR, a sudden nephritic picture, or features suggesting a second disease (low complement, systemic symptoms) should prompt re-biopsy consideration and urgent nephrology review. Pregnancy planning in a patient with significant proteinuria or reduced eGFR warrants early specialist input. Children with IgA nephropathy follow paediatric pathways and should be managed with paediatric nephrology.

Common questions

What is IgA, and why does it damage the kidney?

IgA is an antibody. In IgA nephropathy, abnormal forms of it deposit in the kidney's filters and provoke inflammation. Why the immune system produces the abnormal IgA is not fully understood; genetics and mucosal immunity (throat and gut) both play a part.

What are the typical signs of IgA nephropathy?

Visible blood in the urine during or just after a throat infection is a classic clue. Other patients are found through routine urine testing showing blood or protein, or through rising creatinine. Biopsy confirms the diagnosis and grades activity and scarring.

Do tonsils matter in IgA nephropathy?

Often, yes. Tonsillectomy is practised for IgA nephropathy in Japan, where trials suggested benefit in some groups, but it is not standard practice in most other countries. It is discussed case by case rather than recommended routinely.

What is the long-term outlook?

It varies widely. Some patients keep stable function for decades with blood-pressure and proteinuria control alone; others progress steadily. Proteinuria level over time is the most practical guide to who needs escalation beyond supportive care.

More in Glomerular & Inherited Disease

Related

Related reading

Sources

This Clinical Update is educational content for clinicians and informed patients. It is not medical advice and does not replace the judgment of the treating team. Drug classes are discussed in general terms only; prescribing decisions, doses, and monitoring belong with the patient's own clinicians. Treatment selection in IgA nephropathy depends on biopsy findings, proteinuria, and kidney function; decisions belong with the treating nephrologist.